Atrial Functional Mitral Regurgitation and Tricuspid Regurgitation

NCT ID: NCT05920824

Last Updated: 2025-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

141 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-01

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, observational cohort study designed to identify clinical phenotypes and evaluate predictors \& outcomes of functional mitral and tricuspid valve regurgitation in patients with atrial fibrillation.

Participant will under go:

* Baseline echocardiography
* Cpex Echocardiography
* Blood test: BNP
* 1 year follow up Echocardiography

Participants will be stratified into three subgroups:

* Atrial Functional MR
* Atrial Functional TR
* Mixed MR \& TR

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale

The natural history and risk factors for atrial valve disease are poorly understood and characterised. This study will examine differences between atrial mitral and atrial tricuspid disease and help us understand the natural history of these pathologies.

Study objectives

Primary objective

* Identify \& characterise phenotypes in functional mitral and tricuspid valve regurgitation
* Identify risk factors for progression of disease and outcome.

Secondary objective

Compare the three groups: atrial functional MR, atrial functional TR, and mixed disease, and identify any differences/similarities.

Primary endpoint

Effective Regurgitant Orifice Area at 1 year

Secondary endpoint

* Progression of valve disease defined as worsening of mitral or tricuspid regurgitation \> 1 grade at 1 year.
* Functional: New York Heart Association Class, Predicted VO2max (\<84%).
* Heart Failure admission within 1 year of recruitment.
* Mortality.

Recruitment will take place from the out-patient clinics \& echocardiography laboratory at St Bartholomew's Hospital

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Functional Mitral Regurgitation Functional Tricuspid Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Echocardiogram

Ultrasound scan of the heart

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent
* Age of 18 years or older
* Atrial fibrillation
* Moderate or severe atrial valve disease
* Adequate 2D echocardiography views including parasternal long axis, short axis, apical two chamber, apical three chamber and four chamber.

Exclusion Criteria

* Unwilling or unable to give consent
* Left ventricular impairment (ejection fraction \< 50%).
* Primary/organic valve disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Barts & The London NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sanjeev bhattacharyya

Role: PRINCIPAL_INVESTIGATOR

Barts & The London NHS Trust

Jawza Aldakhil

Role: STUDY_CHAIR

Barts & The London NHS Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Bartholomew's Hospital

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jawza Aldakhil

Role: CONTACT

00447899770693

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jawza Aldakhil

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

326447

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Specific Electrophenotypes in Atrial Fibrillation
NCT05366530 ACTIVE_NOT_RECRUITING